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 TÍTULO: The role of histology and tumor site in downstaging 
after neoadjuvant chemotherapy of gastric cancer 
patients
 OBJECTIVO/
 INTRODUÇÃO: Neoadjuvant chemotherapy for gastric cancer has been 
the standard of care in many centers and downstaging 
after treatment is a major prognostic factor. The aim of 
this study was to identify preoperative predictors of pa-
thological downstaging.
MATERIAL E 
 MÉTODOS: This is a retrospective study that included 168 gastric 
cancer patients treated with neoadjuvant chemothera-
py followed by surgery in a single cancer center be-
tween 2007 and 2014. Exclusion criteria were: gastric 
stump tumors, associated esophagectomy, preoperati-
ve radiotherapy and previously-diagnosed M1 disease. 
Pathological downstaging was defined as ypT0-1-2 or 
stage I tumors.
 RESULTADOS: Preoperative staged tumors were cT3-4 N+ in 80 cases, 
cT3-4 N0 in 73 and cT1-T2 N+ in 15 patients. Downsta-
ged ypT0-1-2 lesions were observed in 74 patients, 19 
individuals had pathological complete response (PCR) 
(11.3%) and another 35 had stage I tumors. Only tumor 
site was associated with more ypT0-1-2 tumors, which 
was more frequent in body and antrum lesions. Age, 
gender, preoperative clinical staging, histology, chemo-
therapy regimen and completeness of treatment had no 
influence. When mixed-type cases were excluded, an 
interaction between tumor site and Lauren histology also 
proved to be a prognostic factor of downstaging, as PCR 
and stage I tumors were more frequent in distal intes-
tinal-type lesions (50%) in comparison with the others.
 DISCUSSÃO: Downstaging was related to tumor site and histology 
and was more frequent in patients with distal intestinal-
-type tumors.
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 TÍTULO: Today, In The Endoscopist Hands
 OBJECTIVO/
 INTRODUÇÃO: Endoscopic submucosal dissection (ESD) was first 
described as a non-surgical promise for early gastric 
epithelial lesions. Over time, ESD applications have ex-
panded. In this context, authors present a case/icono-
graphy and make brief discussion regarding ESD as an 
established modality for curative resection of selected 
gastrointestinal (GI) lesions.
MATERIAL E 
 MÉTODOS: 75 year-old female patient referred to gastroenterolo-
gy outpatient clinic for refractory dyspepsia. Objective 
and analytical examinations were unremarkable. Eso-
phagogastroduodenoscopy (EGD) revealed atrophic 
mucosa at the antrum and a 10x15mm, Paris 0-IIa, flat 
lesion at the lesser curvature of the lower gastric body. 
Biopsies revealed: Intestinal metaplasia and chronic 
active gastritis, both associated to Helicobacter pylo-
ri (HP); tubular low-grade dysplasia adenoma on the 
identified flat lesion.
 RESULTADOS: Patient was referred to a high-volume ESD centre whe-
re endoscopic resection allowed an en block removal 
of the lesion. Diagnosis (WHO): High-grade intraepi-
thelial neoplasia; Vienna Classification: Category 4.1; 
Staging (AJCC): pTis R0. One year endoscopic/histolo-
gical follow-up showed no residual lesions. The patient 
achieved successful HP eradication.
 DISCUSSÃO: This case’s interest is twofold: Points out the role of 
EGD for (pre)malignant gastric lesions screening on a 
both HP and gastric cancer high prevalence country; 
highlights ESD applied for adequate curative non-surgi-
cal resection of GI lesions by trained professionals.
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 TÍTULO: Treatment of Gastric Cancer: outcomes and survi-
val analysis in patients submitted to gastrectomy
 OBJECTIVO/
 INTRODUÇÃO: Gastric cancer (GC) is the 5th most frequently diag-
nosed cancer and the 3rd cause of death from cancer 
worldwide. The objectives of this study were to analyze 
the characteristics, treatment options and overall sur-
vival (OS) of the patients with GC, operated between 
January 2009 and December 2010.
MATERIAL E 
 MÉTODOS: Retrospective analysis of the clinical records of the pa-
tients with GC in which a gastrectomy with curative in-
tent was performed.
 RESULTADOS: 51 patients operated. 33 (65%) were men. Median age 
of 70.6. Most common topographies: antrum (63%), 
body (16%) and fundus (10%). All tumors were adeno-
carcinomas. According to Lauren Classification, 67% 
were intestinal and 33% diffuse type. 65% were at 
stage IB, IIA or IIB. In 69% a partial gastrectomy was 
performed; in those 86% had a Billroth II anastomosis. 
94% did a D1 lymphadenectomy. Overall 30-day posto-
perative mortality of 13,7%. 12% received neoadjuvant 
and adjuvant chemotherapy with MAGIC protocol and 
39% postoperative chemoradiation with Macdonald 
regimen. 21,6% had disease recurrence. The most 
common sites of metastasis were the liver (55%) and 
peritoneum (36%). The OS at 5 years was 65%.
